MCID: BNG095
MIFTS: 41

Benign Giant Cell Tumor

Categories: Bone diseases, Cancer diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Benign Giant Cell Tumor

MalaCards integrated aliases for Benign Giant Cell Tumor:

Name: Benign Giant Cell Tumor 11 14
Giant Cell Tumors 43

Classifications:



External Ids:

Disease Ontology 11 DOID:200
MeSH 43 D005870
NCIt 49 C3055
SNOMED-CT 68 443790001
UMLS 71 C0017525

Summaries for Benign Giant Cell Tumor

MalaCards based summary: Benign Giant Cell Tumor, also known as giant cell tumors, is related to pigmented villonodular synovitis and cherubism. An important gene associated with Benign Giant Cell Tumor is SERPINA3 (Serpin Family A Member 3), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Immunoglobulin G and Immunologic Factors have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and salivary gland, and related phenotypes are homeostasis/metabolism and growth/size/body region

Related Diseases for Benign Giant Cell Tumor

Diseases in the Benign Giant Cell Tumor family:

Malignant Giant Cell Tumor

Diseases related to Benign Giant Cell Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 306)
# Related Disease Score Top Affiliating Genes
1 pigmented villonodular synovitis 32.5 TNFSF11 CSF1R CSF1
2 cherubism 32.4 TNFSF11 CSF1 CALCA
3 bone giant cell tumor 31.8 TNFSF11 SERPINA3 H3-3B H3-3A CTSK CSF1
4 synovitis 31.0 TNFSF11 TNFRSF11B MMP9 CSF1
5 chondroblastoma 30.7 TNFSF11 H3-3B H3-3A
6 giant cell reparative granuloma 30.5 TNFSF11 TNFRSF11A SERPINA3 H3-3A CALCA
7 nodular tenosynovitis 30.5 VIM SERPINA3 PTPRC CSF1R CSF1
8 malignant giant cell tumor 30.5 TNFSF11 H3-3B H3-3A
9 tenosynovial giant cell tumor 30.4 SERPINA3 CSF1R CSF1
10 chondrosarcoma 30.4 VIM SERPINA3 MUC1 DES
11 osteitis fibrosa 30.3 FGF23 CALCA BGLAP
12 osteoarthritis 30.3 TNFSF11 TNFRSF11B MMP9 CTSK BGLAP
13 fibroma 30.3 VIM SERPINA3 DES ACTC1
14 bone giant cell sarcoma 30.3 TNFSF11 H3-3B H3-3A
15 malignant giant cell tumor of the tendon sheath 30.2 CSF1R CSF1
16 hyperparathyroidism 30.2 TNFSF11 TNFRSF11B FGF23 CALCA BGLAP
17 synovium neoplasm 30.2 CSF1R CSF1
18 osteoblastoma 30.2 TNFSF11 FGF23 BGLAP
19 arthropathy 30.1 TNFSF11 TNFRSF11B TNFRSF11A
20 osteomyelitis 30.1 TNFSF11 TNFRSF11A CTSK CALCA
21 hemangioma 30.1 VIM MUC1 MMP9 CALCA ACTC1
22 osteogenic sarcoma 30.1 TNFSF11 TNFRSF11B TNFRSF11A MMP9 BGLAP
23 angiosarcoma 30.1 VIM SERPINA3 MUC1 ACTC1
24 primary hyperparathyroidism 30.0 TNFSF11 FGF23 CALCA BGLAP
25 chordoma 30.0 VIM SERPINA3 MUC1 MMP9 DES
26 paget's disease of bone 30.0 TNFSF11 TNFRSF11B TNFRSF11A CTSK CALCA BGLAP
27 telangiectatic osteogenic sarcoma 29.9 TNFSF11 H3-3B H3-3A CALCA
28 root resorption 29.9 TNFSF11 TNFRSF11B TNFRSF11A MMP9 CALCA
29 ossifying fibroma 29.9 SERPINA3 H3-3B H3-3A FGF23
30 fibrous dysplasia 29.9 TNFSF11 TNFRSF11A FGF23 CALCA BGLAP
31 cutaneous fibrous histiocytoma 29.9 SERPINA3 MITF DES ACTC1
32 leiomyosarcoma 29.9 VIM SERPINA3 MUC1 DES ACTC1
33 anaplastic large cell lymphoma 29.8 PTPRC MUC1 CSF1R
34 fibrous histiocytoma 29.7 VIM SERPINA3 MITF DES ACTC1
35 ewing sarcoma 29.7 VIM PTPRC DES CSF1R
36 mammary paget's disease 29.7 TNFSF11 TNFRSF11B TNFRSF11A MUC1 CTSK CALCA
37 malignant peripheral nerve sheath tumor 29.7 VIM MITF ACTC1
38 sarcoma 29.7 VIM SERPINA3 PTPRC MUC1 DES CSF1R
39 malignant fibrous histiocytoma 29.5 VIM SERPINA3 PTPRC MUC1 DES ACTC1
40 bone disease 29.2 TNFSF11 TNFRSF11B TNFRSF11A SERPINA3 MMP9 FGF23
41 testicular germ cell tumor 10.6
42 villonodular synovitis 10.4
43 malignant ovarian brenner tumor 10.4 TNFSF11 CALCA
44 temporomandibular joint anomaly 10.4 TNFSF11 TNFRSF11B
45 periodontitis, chronic 10.4 TNFSF11 TNFRSF11B
46 retroperitoneal fibrosis 10.4 VIM PTPRC
47 heart lymphoma 10.4 VIM PTPRC
48 tuberous sclerosis 1 10.3
49 tuberous sclerosis 2 10.3
50 tuberous sclerosis 10.3

Graphical network of the top 20 diseases related to Benign Giant Cell Tumor:



Diseases related to Benign Giant Cell Tumor

Symptoms & Phenotypes for Benign Giant Cell Tumor

GenomeRNAi Phenotypes related to Benign Giant Cell Tumor according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.15 ACTC1 ADAM12 BGLAP CALCA CSF1 CSF1R
2 no effect GR00402-S-2 10.15 ACTC1 ADAM12 BGLAP CALCA CSF1 DES

MGI Mouse Phenotypes related to Benign Giant Cell Tumor:

45 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.5 ACTC1 BGLAP CALCA CSF1 CSF1R CTSK
2 growth/size/body region MP:0005378 10.32 ACTC1 CSF1 CSF1R CTSK FGF23 H3-3A
3 behavior/neurological MP:0005386 10.31 ACTC1 CALCA CSF1 CSF1R CTSK DES
4 cellular MP:0005384 10.3 ACTC1 BGLAP CSF1 CSF1R CTSK DES
5 normal MP:0002873 10.27 ACTC1 CALCA CSF1R H3-3A H3-3B MITF
6 immune system MP:0005387 10.22 BGLAP CSF1 CSF1R CTSK FGF23 MITF
7 limbs/digits/tail MP:0005371 10.19 CSF1 CSF1R CTSK FGF23 MITF MMP9
8 endocrine/exocrine gland MP:0005379 10.19 BGLAP CSF1 CSF1R CTSK FGF23 MITF
9 renal/urinary system MP:0005367 10.15 CALCA FGF23 H3-3A H3-3B MITF MMP9
10 reproductive system MP:0005389 10.13 BGLAP CSF1 CSF1R CTSK FGF23 H3-3A
11 no phenotypic analysis MP:0003012 10.1 CSF1 CSF1R MITF MUC1 PTPRC TNFRSF11A
12 skeleton MP:0005390 10.03 BGLAP CALCA CSF1 CSF1R CTSK FGF23
13 craniofacial MP:0005382 10.02 CSF1 CSF1R CTSK MITF TNFRSF11A TNFRSF11B
14 respiratory system MP:0005388 10.02 CALCA CSF1 CTSK FGF23 MMP9 PTPRC
15 hematopoietic system MP:0005397 10 ACTC1 BGLAP CSF1 CSF1R CTSK FGF23
16 mortality/aging MP:0010768 9.86 ACTC1 ADAM12 CALCA CSF1 CSF1R DES
17 integument MP:0010771 9.4 CALCA CSF1 CSF1R FGF23 MITF MMP9

Drugs & Therapeutics for Benign Giant Cell Tumor

Drugs for Benign Giant Cell Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 50)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Immunoglobulin G Phase 4
2 Immunologic Factors Phase 4
3
Phenol Approved, Experimental Phase 3 108-95-2 996
4
Ethanol Approved Phase 3 64-17-5 702
5 Polymethyl Methacrylate Phase 3
6 Diphosphonates Phase 3
7
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
8
Fludarabine Approved Phase 2 75607-67-9, 21679-14-1 30751 657237
9
Aldesleukin Approved Phase 2 110942-02-4
10
Nivolumab Approved Phase 2 946414-94-4
11
Ipilimumab Approved Phase 2 477202-00-9
12
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
13
Zoledronic acid Approved Phase 2 118072-93-8 68740
14
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 67-97-0, 1406-16-2 5280795 10883523
15 Protein Kinase Inhibitors Phase 2
16 Grapefruit Seed Extract Phase 2
17 Immunoglobulins Phase 2
18 Antibodies, Monoclonal Phase 2
19 Antibodies Phase 2
20 Alkylating Agents Phase 2
21 Antiviral Agents Phase 2
22 Antirheumatic Agents Phase 2
23 Anti-Retroviral Agents Phase 2
24 Antineoplastic Agents, Alkylating Phase 2
25 Immune Checkpoint Inhibitors Phase 2
26 Interleukin-2 Phase 2
27 Anti-HIV Agents Phase 2
28 Analgesics, Non-Narcotic Phase 2
29 Analgesics Phase 2
30 Antineoplastic Agents, Immunological Phase 2
31 Immunosuppressive Agents Phase 2
32 Vitamins Phase 1, Phase 2
33 Trace Elements Phase 1, Phase 2
34 Calciferol Phase 1, Phase 2
35 Hormones Phase 1, Phase 2
36 Calcium, Dietary Phase 1, Phase 2
37 Micronutrients Phase 1, Phase 2
38 Immunoglobulins, Intravenous Phase 2
39 Anti-Bacterial Agents Phase 2
40 Anti-Infective Agents Phase 2
41 Vasodilator Agents Phase 2
42 Gentamicins Phase 2
43 Protective Agents Phase 2
44 Paraproteins Phase 2
45 Myeloma Proteins Phase 2
46 Pharmaceutical Solutions Phase 2
47
Serine Investigational, Nutraceutical Phase 2 56-45-1 5951
48
Calcium Nutraceutical Phase 1, Phase 2 7440-70-2 271
49
Denosumab Approved 615258-40-7
50 Calcium Supplement

Interventional clinical trials:

(show all 39)
# Name Status NCT ID Phase Drugs
1 Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004 Active, not recruiting NCT03301857 Phase 4 Denosumab (Cohort A)
2 A Phase 4, Multicenter Study to Evaluate Discontinuation and Re-Treatment in Subjects With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib Active, not recruiting NCT04526704 Phase 4 Pexidartinib
3 An Open-label, Multi-center, Phase 4 Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone Not yet recruiting NCT04586660 Phase 4 XGEVA®
4 Clinical, Pathologic Characteristics and Its Mechansim of Denosumab Treated Giant Cell Tumor of Bone Unknown status NCT03259152 Phase 3 Denosumab
5 A Double-blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects With Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath Completed NCT02371369 Phase 3 Pexidartinib;Placebo
6 A Phase 3, Randomized, Placebo-controlled, Double-blind Study of Vimseltinib to Assess the Efficacy and Safety in Patients With Tenosynovial Giant Cell Tumor (MOTION) Recruiting NCT05059262 Phase 3 vimseltinib;Placebo
7 Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone: A Prospective Randomized Controlled Trial Recruiting NCT03295981 Phase 3 Zoledronic Acid
8 Multicenter, Single Arm Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With Tenosynovial Giant Cell Tumor Active, not recruiting NCT04488822 Phase 3 Pexidartinib
9 A Phase 3, Randomized, Placebo-controlled, Double-Blind Study of Emactuzumab to Assess Efficacy and Safety in Subjects With Tenosynovial Giant Cell Tumor (TANGENT) Active, not recruiting NCT05417789 Phase 3 Emactuzumab;Placebo
10 An Open-label, Multi-center, Phase 2 Study of Denosumab in Subjects With Giant Cell Tumor of Bone Completed NCT00680992 Phase 2 Denosumab
11 An Open-Label, Multi-Center, Phase 2 Safety and Efficacy Study of Denosumab (AMG 162) in Subjects With Recurrent or Unresectable Giant Cell Tumor (GCT) of Bone Completed NCT00396279 Phase 2
12 A Phase II Trial of Dasatinib in Advanced Sarcomas Completed NCT00464620 Phase 2 Dasatinib
13 A Phase II Randomized, Double -Blind, Placebo Controlled Study to Assess Safety, Tolerability and Effect on Tumor Size of MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) Completed NCT01643850 Phase 2 MCS110;Placebo
14 A Phase 1/2 Study of Cabiralizumab, an Anti-CSF1 Receptor Antibody, in Patients With Pigmented Villonodular Synovitis (PVNS)/ Diffuse Type Tenosynovial Giant Cell Tumor (Dt-TGCT) Completed NCT02471716 Phase 1, Phase 2
15 Phase II Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT) Completed NCT01261429 Phase 2 Tasigna
16 A Phase 2, Multicenter, Two-Part, Open-Label Study of Pexidartinib in Adult Subjects With Tenosynovial Giant Cell Tumor in Japan Recruiting NCT04703322 Phase 2 Pexidartinib
17 A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor Recruiting NCT03069469 Phase 1, Phase 2 DCC-3014
18 Clinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types Recruiting NCT03449108 Phase 2 Cyclophosphamide;Fludarabine
19 An Adaptive, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee Active, not recruiting NCT04731675 Phase 2
20 A Phase Ib/II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of JMT103 in Surgically Unsalvageable or Refractory Giant Cell Tumor of Bone Active, not recruiting NCT04255576 Phase 1, Phase 2
21 A Phase 2, Adaptive, Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Intravenous AMB-05X in Subjects With Tenosynovial Giant Cell Tumor Active, not recruiting NCT04938180 Phase 2
22 A Multi-Center Single Agent Phase II Study of the Efficacy of Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor Active, not recruiting NCT01207492 Phase 2 nilotinib
23 Zoledronic Acid-loaded Bone Cement as a Local Adjuvant Therapy for Giant Cell Bone Tumor After Intralesional Curettage: a Prospective, Multicenter, Single Blinded, Randomized Control Trial. Not yet recruiting NCT05595603 Phase 2
24 A Phase 2, Open-Label, Adaptive, Dose-Ranging Study With Long-Term Extension to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Intra Articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor Not yet recruiting NCT05349643 Phase 2
25 Reduced Dose-density of Denosumab for Maintenance Therapy of Unresectable Giant Cell Tumor of Bone: a Multicenter Phase II Study "REDUCE" Terminated NCT03620149 Phase 2 Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
26 Adjuvant Zoledronic Acid in 'High Risk' Giant Cell Tumour of Bone (GCT) - A Randomized Phase II Study Terminated NCT00889590 Phase 2 Zoledronic acid
27 Phase 2 Study of the Effect of Zoledronate on Local Recurrence After Surgical Treatment of Giant Cell Tumors of Bone Terminated NCT01564121 Phase 1, Phase 2 acid Zoledronic
28 A Phase 1, Open-Label Study of ABSK021 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Solid Tumor Recruiting NCT04192344 Phase 1 ABSK021
29 A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX73086 as a Single Agent in Subjects With Advanced Solid Tumors and in Subjects With Locally Advanced or Refractory Tenosynovial Giant Cell Tumor (TGCT) Terminated NCT02673736 Phase 1 PLX73086
30 A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX7486 as a Single Agent in Patients With Advanced Solid Tumors Terminated NCT01804530 Phase 1 PLX7486 TsOH
31 Safety and Efficacy of Post-operative Denosumab Strategy for Giant Cell Tumor of Bone Treatment in China:Correlation Between Recurrence and Drug Withdrawl Unknown status NCT03358212 Denosumab
32 Il Tumore a Cellule Giganti Delle estermità Completed NCT02996734
33 Giant Cell Tumor of the Bone in Patients Under 15 Years Old: a Single Institution Case-series Completed NCT04002817
34 A Disease Registry for Patients With Tenosynovial Giant Cell Tumors (TGCT), Also Known as Pigmented Villonodular Synovitis (PVNS) and Giant Cell Tumor of the Tendon Sheath (GCT-TS) Completed NCT02948088
35 Radiomics Based on Preoperative Imaging of Giant Cell Tumor of the Spine to Predict the Early Recurrence and Survival of Giant Cell Tumor of the Spine After Surgery, and the Expression Levels of P53, VEGF, RANK, RANKL and Other Prognostic-related Molecular Markers. Completed NCT04952818
36 A Real-world Study on Patients of Surgically Unsalvageable or Severe Post-surgery Morbidity Associated Giant Cell Tumor of Bone Completed NCT05402865 Denosumab
37 Oral Care of Patients Treated With Anti-RANK-ligand Antibodies for a Giant Cell Tumour: Retrospective Study at the University Hospitals of Strasbourg Recruiting NCT05542524
38 A Long-term Study to Further Evaluate the Risk of Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment Recruiting NCT04635111 TURALIO™
39 InAdvance: Surveillance, Prevention, and Interception in a Population at Risk For Cancer Not yet recruiting NCT05463796

Search NIH Clinical Center for Benign Giant Cell Tumor

Cochrane evidence based reviews: giant cell tumors

Genetic Tests for Benign Giant Cell Tumor

Anatomical Context for Benign Giant Cell Tumor

Organs/tissues related to Benign Giant Cell Tumor:

MalaCards : Bone, Lung, Salivary Gland, Bone Marrow, Pancreas, Ovary

Publications for Benign Giant Cell Tumor

Articles related to Benign Giant Cell Tumor:

(show top 50) (show all 156)
# Title Authors PMID Year
1
Clinical case seminar: Fibroblast growth factor 23: a new clinical marker for oncogenic osteomalacia. 53 62
12970268 2003
2
Clinical and radiological outcomes of combined modular prothesis and cortical strut for revision proximal femur in giant cell tumor of bone patients. 62
35491561 2022
3
Primary malignant giant cell tumor of the sternum. 62
34249788 2021
4
A giant cell rich osteosarcoma of the proximal ulnar bone treated by elbow arthroplasty: A case report. 62
31048211 2019
5
Malignancy in Giant Cell Tumor of Bone: A Review of the Literature. 62
30935298 2019
6
Malignant Sarcomatous Transformation of Benign Giant Cell Tumor of Bone after Treatment with Denosumab Therapy: A Literature Review of Reported Cases. 62
30868006 2018
7
Epidemiology of benign giant cell tumor of bone in the Chinese population. 62
30148063 2018
8
Transformation of Benign Giant Cell Tumor of Bone Into Epithelioid Angiosarcoma. 62
29309463 2017
9
Clinical characteristics and risk factors analysis of lung metastasis of benign giant cell tumor of bone. 62
28443231 2017
10
A solitary pleural metastasis of benign giant cell tumor of bone. 62
27516881 2016
11
Polypoid extrahepatic bile duct carcinoma morphologically indistinguishable from benign giant cell tumor. 62
26256450 2016
12
Giant Cell Tumor of the Tendon Sheath With Discordant Metabolism as a False Positive on Staging of Mantle Cell Lymphoma. 62
26053722 2015
13
A High-grade Sarcoma Arising in a Patient With Recurrent Benign Giant Cell Tumor of the Proximal Tibia While Receiving Treatment With Denosumab. 62
25758379 2015
14
Endobronchial metastasis in benign giant cell tumor of bone in a 25-year male -Second case report with literature review. 62
26180400 2015
15
Differential Expression of ADAM23, CDKN2A (P16), MMP14 and VIM Associated with Giant Cell Tumor of Bone. 62
26078788 2015
16
Benign giant-cell tumor of the common bile duct: a case report. 62
25386094 2014
17
Cytologic findings from a benign giant cell tumor of the tendon sheath in a dog. 62
24730372 2014
18
The hypermetabolic giant: 18F-FDG avid giant cell tumor identified on PET-CT. 62
25426232 2014
19
Dedifferentiated chondrosarcoma mimicking a giant cell tumor. Is this low grade dedifferentiated chondrosarcoma? 62
24405942 2014
20
Triple-phase dynamic MRI: a new clue to predict malignant transformation of giant cell tumor of bone. 62
24239410 2014
21
Pigmented villous nodular synovitis mimicking metastatic melanoma on PET-CT. 62
24705190 2014
22
Giant cell tumor of the extremity: retrospective analysis of 621 Chinese patients from one institution. 62
22398741 2012
23
An uncommon presentation of giant cell tumor. 62
22125733 2011
24
Isolated cardiac metastasis from a histologically "benign" giant-cell tumor of the distal end of the femur: a case report. 62
21084583 2010
25
[Aneurysmatic bone cyst coexisting with osteosarcoma. Radiopathologic discussion]. 62
20304449 2010
26
CCAAT/enhancer binding protein beta is up-regulated in giant cell tumor of bone and regulates RANKL expression. 53
20225273 2010
27
Translating gene expression into clinical care: sarcomas as a paradigm. 53
20194847 2010
28
Cytogenetic analysis of a primary bone angiosarcoma. 53
19737647 2009
29
Fine-needle aspiration of brown tumor of bone: cytologic features with radiologic and histologic correlation. 62
19021196 2009
30
Giant cell tumor of bone: treatment and outcome of 214 cases. 62
18322700 2008
31
Three cases of benign giant cell tumor with unusual imaging features. 62
18760733 2008
32
Primary malignant giant cell tumor of bone: a series of three rare cases. 62
17592717 2007
33
Benign giant cell tumor of the spine: an unusual indication for radiotherapy. 62
16810546 2006
34
RANK Expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone. 53
16939392 2006
35
[Expression of macrophage inflammatory protein-1alpha, a disintegrin-like and metalloproteinase 8 and 12, and CD68 protein in giant cell lesions of jaw and giant cell tumors of long bone]. 53
16251041 2005
36
Giant cell tumors of the bone: molecular profiling and expression analysis of Ephrin A1 receptor, Claudin 7, CD52, FGFR3 and AMFR. 53
16325507 2005
37
Immunohistochemical evaluation of microphthalmia-associated transcription factor expression in giant cell lesions. 53
15205688 2004
38
Cathepsin K is the principal protease in giant cell tumor of bone. 53
15277232 2004
39
Osteoclast-type giant cell neoplasm of salivary gland. A microdissection-based comparative genotyping assay and literature review: extraskeletal "giant cell tumor of bone" or osteoclast-type giant cell "carcinoma"? 53
15223968 2004
40
Giant cell tumor and Paget's disease of bone in one family: geographic clustering. 62
15123951 2004
41
Spontaneous malignant transformation of conventional giant cell tumor. 62
14749901 2004
42
Expression of VEGF and MMP-9 in giant cell tumor of bone and other osteolytic lesions. 53
12850503 2003
43
Ductal adenocarcinoma of the pancreas with huge cystic degeneration: a lesion to be distinguished from pseudocyst and mucinous cystadenocarcinoma. 53
12894360 2003
44
[Giant-cell tumor of the patella with lung metastases: a case report]. 62
12844041 2003
45
Malignancy in giant cell tumor. 62
12605278 2003
46
Gene expression of osteoprotegerin and osteoclast differentiation factor in giant cell tumor. 53
12419159 2002
47
RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone. 53
11863217 2002
48
Giant cell tumor of bone. The role of fibroblast growth factor 3 positive mesenchymal stem cells in its pathogenesis. 53
12865629 2002
49
[Expression of ADAM12 (Meltrin-alpha) gene in giant cell tumor of bone]. 53
11769731 2001
50
[Expression and significance of urokinase-type plasminogen activator, its receptor, and type 2 inhibitor in giant cell tumor of bone]. 53
11810768 2001

Variations for Benign Giant Cell Tumor

Expression for Benign Giant Cell Tumor

Search GEO for disease gene expression data for Benign Giant Cell Tumor.

Pathways for Benign Giant Cell Tumor

Pathways related to Benign Giant Cell Tumor according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.7 CSF1 CSF1R CTSK MMP9 MUC1 PTPRC
2
Show member pathways
13.62 CSF1 CSF1R FGF23 H3-3A H3-3B MUC1
3
Show member pathways
12.84 VIM TNFSF11 TNFRSF11B TNFRSF11A MUC1 MMP9
4 12.44 MMP9 FGF23 CSF1R CSF1 ACTC1
5 12.36 VIM MUC1 DES ACTC1
6 12.05 TNFSF11 TNFRSF11B FGF23 BGLAP
7 11.79 VIM MUC1 MMP9
8
Show member pathways
11.73 MMP9 CTSK ADAM12
9 11.7 PTPRC DES BGLAP
10
Show member pathways
11.57 VIM DES ACTC1
11 11.56 PTPRC CSF1R CSF1
12 11.37 MMP9 FGF23 BGLAP
13 11.23 TNFSF11 CSF1R CSF1
14 11.02 TNFSF11 TNFRSF11B TNFRSF11A
15 11.01 TNFSF11 TNFRSF11B TNFRSF11A CALCA BGLAP
16 11 TNFSF11 TNFRSF11B TNFRSF11A CTSK CSF1 CALCA
17 10.64 VIM TNFSF11 FGF23 DES CSF1R CSF1
18 10.58 TNFSF11 TNFRSF11A

GO Terms for Benign Giant Cell Tumor

Cellular components related to Benign Giant Cell Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 10.2 TNFSF11 TNFRSF11B SERPINA3 MUC1 MMP9 FGF23
2 extracellular region GO:0005576 9.72 TNFSF11 TNFRSF11B SERPINA3 MUC1 MMP9 H3-3B
3 CSF1-CSF1R complex GO:1990682 9.26 CSF1 CSF1R

Biological processes related to Benign Giant Cell Tumor according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.28 VIM TNFSF11 MITF FGF23 CSF1 ACTC1
2 response to mechanical stimulus GO:0009612 10.03 TNFRSF11A CSF1 BGLAP
3 monocyte chemotaxis GO:0002548 9.99 TNFSF11 TNFRSF11A CALCA
4 response to organic cyclic compound GO:0014070 9.98 BGLAP CSF1 CTSK TNFRSF11A
5 macrophage differentiation GO:0030225 9.88 MMP9 CSF1R CSF1
6 microglial cell proliferation GO:0061518 9.85 CSF1R CSF1
7 positive regulation of macrophage proliferation GO:0120041 9.83 CSF1 CSF1R
8 TNFSF11-mediated signaling pathway GO:0071847 9.8 TNFSF11 TNFRSF11A
9 osteoclast proliferation GO:0002158 9.78 TNFSF11 CSF1
10 macrophage colony-stimulating factor signaling pathway GO:0038145 9.76 CSF1R CSF1
11 positive regulation of ERK1 and ERK2 cascade via TNFSF11-mediated signaling GO:0071848 9.67 TNFSF11 TNFRSF11A
12 regulation of osteoclast differentiation GO:0045670 9.65 TNFSF11 MITF BGLAP
13 osteoclast differentiation GO:0030316 9.65 TNFSF11 TNFRSF11A MITF CSF1R CSF1
14 cellular response to zinc ion starvation GO:0034224 9.63 BGLAP CTSK TNFRSF11A
15 positive regulation of fever generation by positive regulation of prostaglandin secretion GO:0071812 9.62 TNFSF11 TNFRSF11A
16 ossification GO:0001503 9.36 TNFSF11 TNFRSF11A MMP9 CSF1 CALCA BGLAP

Sources for Benign Giant Cell Tumor

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....